Pricing And Commercial Strategies For Emerging Markets Need To Be Built Into Drug Development Programs Early - DIA Conference
This article was originally published in PharmAsia News
Executive Summary
CHICAGO - Emerging markets represent a plethora of opportunity for multinational pharma companies, but they also represent a confusing mix of pricing and reimbursement policies that change rapidly and are not always clear
You may also be interested in...
Asia Public Health Care Expansion Hinges On Cost Control Solutions
Asia can avoid blowing budgets by focusing on preventative care as an unprecedented increase in public spending on health care gains momentum in developing countries such as Indonesia and the Philippines.
PharmAsia News Favorite Stories From 2011
If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.
Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?
A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government